Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

This is an open-label, prospective and exploratory clinical study to evaluate the efficacy and safety of JAK inhibitor SHR-0302 in combination with EZH2 inhibitor SHR-2554 in patients with R/R PTCL. The study plans to enroll approximately 25 patients. 6-12 patients will receive SHR-0302 monotherapy and SHR-0302+SHR-2554 combination therapy in the safety run-in phase. According to the safety observed, the investigators discuss and decide to select a dose group to explore the efficacy and safety. 13 patients may be enrolled in the expansion phase.

Trial Details

NCT ID
NCT06519526
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • SHR-0302
  • SHR-2554
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Males or females aged 18-70 years (inclusive);
  • Histologically confirmed peripheral T-cell lymphoma;
  • Disease status defined as relapsed or refractory after \>=1 prior systemic treatment lines;
  • Have measurable lesions;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →